Seer, Inc. (SEER)
SEERNASDAQ-GSBiotechnology: Laboratory Analytical Instruments
$1.55
-0.1300 (-7.74%) today
At the close, Nov 10, 4:00 PM ET. After hours $1.55 -3.73%
- Market cap
- $89.15m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- $1.57 to $1.70
- 52-week range
- $1.55 to $2.38
- Average volume
- 228.6k
- Previous close
- $1.68
Analysts
2 coveringStrong Buy2 buy, 0 hold, 0 sell
Targets a year out average $4.00, +158.1% from here
Earnings
Next report
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $4.12m | $4.20m | $2.79m | $3.10m |
| Gross profit | $2.11m | $2.18m | $982.0k | $1.51m |
| Operating income | -$19.35m | -$17.39m | -$17.26m | -$16.84m |
| Net income | -$18.23m | -$15.99m | -$16.84m | -$16.90m |
Last four quarters: revenue $14.22m, margin -478.1%, free cash flow -$44.23m
News
8 latest- Seer, Inc. to Announce Second Quarter 2025 Financial Results on August 6, 2025Quiver Quantitative · Jul 22, 2025
- Insider Sale: Director at $SEER Sells 30,253 SharesQuiver Quantitative · Jun 16, 2025
- Seer, Inc. and Korea University Launch First Large-Scale Study to Identify Early-Onset Cancer Biomarkers Using Proteograph ONE AssayQuiver Quantitative · Jun 1, 2025
- $SEER stock is up 13% today. Here's what we see in our data.Quiver Quantitative · May 14, 2025
- $SEER Earnings Results: $SEER Reports Quarterly EarningsQuiver Quantitative · May 13, 2025
- Seer, Inc. Reports Strong First Quarter 2025 Financial Results with $4.2 Million in RevenueQuiver Quantitative · May 13, 2025
- Seer, Inc. to Report Q1 2025 Financial Results on May 13, 2025Quiver Quantitative · Apr 24, 2025
- Seer, Inc. to Showcase Innovations in Proteomics at US HUPO 2025 Annual ConferenceQuiver Quantitative · Feb 20, 2025
The company
Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics-delivering insights with scale, speed, precision, and reproducibility previously unattainable by other proteomic methods. Seer's Proteograph Product Suite uniquely integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables, and advanced analytical software to solve challenges conventional methods have failed to overcome. Traditional proteomic technologies have struggled with inconsistent data, limited throughput, and prohibitive complexity, but Seer's robust and scalable workflow consistently reveals biological insights that others do not. Seer's products are for research use only and are not intended for diagnostic procedures. For more information about Seer's differentiated approach and ongoing leadership in proteomics, visit www.seer.bio.
- Sector
- Industrials
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- seer.bio
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.